血液科

订阅

MedSci主页 / 所有栏目 / 血液科

Leuk Lymphoma：地西他滨单药治疗复发性/难治性AML 疗效几何？

2017-07-17 梁舒瑶 吴星 环球医学

AML地西他滨
关注

复发性/难治性急性髓细胞性白血病（AML）治疗方法的改善仍然面临挑战。2017年9月，发表在《Leuk Lymphoma》的一项回顾性分析调查了地西他滨单药治疗复发性/难治性AML患者的疗效。 研究者对34例使用地西他滨的复发性/难治性AML患者（中位年龄62岁；中位Charlson并存病得分，6）的结局开展了一项回顾性分析。每日给予地西他滨20mg/m2，采用5天（25%）或10天（75%）一

复发性/难治性急性髓细胞性白血病（AML）治疗方法的改善仍然面临挑战。2017年9月，发表在《Leuk Lymphoma》的一项回顾性分析调查了地西他滨单药治疗复发性/难治性AML患者的疗效。

研究者对34例使用地西他滨的复发性/难治性AML患者（中位年龄62岁；中位Charlson并存病得分，6）的结局开展了一项回顾性分析。每日给予地西他滨20mg/m2，采用5天（25%）或10天（75%）一个周期。总应答率（OR）为30%，21%为完全缓解，9%为部分缓解。治疗相关髓系肿瘤（t-MN）和继发AML患者的OR显着高于初发AML的患者（70% vs 30%； p=0.02）。所有患者的中位总生存为8.5个月。t-MN或继发AML患者的中位生存为12.4个月，而初发AML患者的中位生存为8个月（p=0.20）。15例（44%）继续造血干细胞移植。这些数据支持，复发性/难治性AML患者使用10天一个周期的地西他滨，尤其是对于继发或治疗相关AML患者。

原始出处：

Khan N, Hantel A, et al. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma. 2017 Sep;58(9):1-7. doi: 10.1080/10428194.2017.1289524.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1689289, encodeId=685c1689289a1, content=<a href='/topic/show?id=1ddd11158fb' target=_blank style='color:#2F92EE;'>#lymphoma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11158, encryptionId=1ddd11158fb, topicName=lymphoma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45ae28785510, createdName=ms5187542471278033, createdTime=Tue Aug 22 03:02:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909647, encodeId=5c4b190964e35, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Mar 11 04:02:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687699, encodeId=f377168e6998c, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Sat May 26 06:02:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528364, encodeId=07101528364ae, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Jul 19 08:02:00 CST 2017, time=2017-07-19, status=1, ipAttribution=)]
    2017-08-22 ms5187542471278033

    #lymphoma#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1689289, encodeId=685c1689289a1, content=<a href='/topic/show?id=1ddd11158fb' target=_blank style='color:#2F92EE;'>#lymphoma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11158, encryptionId=1ddd11158fb, topicName=lymphoma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45ae28785510, createdName=ms5187542471278033, createdTime=Tue Aug 22 03:02:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909647, encodeId=5c4b190964e35, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Mar 11 04:02:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687699, encodeId=f377168e6998c, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Sat May 26 06:02:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528364, encodeId=07101528364ae, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Jul 19 08:02:00 CST 2017, time=2017-07-19, status=1, ipAttribution=)]
    2018-03-11 hb2008ye

    #复发性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1689289, encodeId=685c1689289a1, content=<a href='/topic/show?id=1ddd11158fb' target=_blank style='color:#2F92EE;'>#lymphoma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11158, encryptionId=1ddd11158fb, topicName=lymphoma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45ae28785510, createdName=ms5187542471278033, createdTime=Tue Aug 22 03:02:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909647, encodeId=5c4b190964e35, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Mar 11 04:02:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687699, encodeId=f377168e6998c, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Sat May 26 06:02:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528364, encodeId=07101528364ae, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Jul 19 08:02:00 CST 2017, time=2017-07-19, status=1, ipAttribution=)]
    2018-05-26 12498717m75(暂无昵称)

    #单药治疗#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1689289, encodeId=685c1689289a1, content=<a href='/topic/show?id=1ddd11158fb' target=_blank style='color:#2F92EE;'>#lymphoma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11158, encryptionId=1ddd11158fb, topicName=lymphoma)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45ae28785510, createdName=ms5187542471278033, createdTime=Tue Aug 22 03:02:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909647, encodeId=5c4b190964e35, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Mar 11 04:02:00 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1687699, encodeId=f377168e6998c, content=<a href='/topic/show?id=be223633375' target=_blank style='color:#2F92EE;'>#单药治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36333, encryptionId=be223633375, topicName=单药治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2bef28414326, createdName=12498717m75(暂无昵称), createdTime=Sat May 26 06:02:00 CST 2018, time=2018-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528364, encodeId=07101528364ae, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Wed Jul 19 08:02:00 CST 2017, time=2017-07-19, status=1, ipAttribution=)]
    2017-07-19 freve

    #难治性#

    0

相关资讯

“饿死”癌细胞的药物IACS-10759已进入临床试验阶段

美国MD安德森癌症中心应用癌症科学研究所（IACS）对一个旨在“饿死”癌细胞的新药启动了首项临床研究，该药物编号为IACS-10759。该研究将招募急性髓系白血病病人参与研究，并得到了白血病和淋巴瘤学会治疗加速项目的350万美元支持。“我们非常高兴这项里程碑研究得到了白血病和淋巴瘤学会治疗加速项目的支持，我们希望能够尽快看到病人对IACS-10759这种药物产生良好的应答，就像我们在临床前模型观察

Leuk Lymphoma：阿扎胞苷或可降低老年AML患者不良事件发生率

阿扎胞苷是一种新型表观遗传学抗肿瘤药。2017年6月，发表在《Leuk Lymphoma》的一项研究表明，急性髓细胞性白血病老年患者中，与常规治疗方案相比，阿扎胞苷可降低治疗中出现的不良事件及其相关住院的发生率。

Lancet Oncol：Gilteritinib可选择性抑制复发或难治性AML的FLT3突变

约三成的复发或难治性AML患者会出现FLT3突变。体外试验显示，gilteritinib可对FLT3选择性抑制，但是还没有人体试验数据。6月20日在线发表于Lancet Oncology上的一篇文章表示，FLT3突变的复发或难治性AML患者中，gilteritinib的安全性特征良好，应答持续时间长，总体生存结局令人鼓舞。

FDA批准急性髓性白血病（AML）靶向新药midostaurin

FDA 4月28日批准诺华Rydapt (midostaurin)，用于联合化疗一线治疗携带FLT3突变的新确诊成人急性髓性白血病。FDA同时批准了Invivoscribe Technologies公司的伴随诊断试剂盒LeukoStrat CDx FLT3。

Nature：17个基因可预测AML患者的生存

多伦多大学领导的一个国际研究小组发现，来自白血病干细胞的17个基因的标签，可以预测急性骨髓性白血病（AML）患者对治疗的响应情况。他们分析了78名AML患者样本中白血病干细胞和非白血病干细胞之间的基因表达差异，找到了17个差异表达的核心基因。这组基因的评分高与不良预后相关，可以用来识别不能从标准治疗中受益的患者。相关研究结果发表在Nature上。文章作者Jean Wang说，“不论AML患者在哪里

Leuk Lymphoma：AML青少年和年轻人生存期存在种族差异

很少有研究检测了种族对急性髓性白血病（AML）的青少年和年轻人（AYA）生存期的影响。2017年5月，发表在《Leuk Lymphoma》的一项使用美国国家癌症数据库的回顾性研究对此进行分析。